Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Talazoparib Tosylate | Talzenna | 4.5. Interactions with other medicinal products | Interactions with P-gp inducer, rifampin, and rifampin | Mar,2023 |
| Fentanyl | Abstral | 4.5. Interactions with other medicinal products | Interaction with gabapentinoids (gabapentin and pregabalin) | Aug, 2024 |
| Omeprazole | Losec Mups | 4.4 Special Warnings and Special Precautions for Use , 4.8 Undesirable effects | Acute tubulointerstitial nephritis , Tubulointerstitial nephritis | Jan,2023 |
| Cefuroxime | Zinnat | 4.4 Special Warnings and Special Precautions for Use , 4.8 Undesirable effects | Hypersensitivity reactions, Severe cutaneous adverse reactions. Drug Reaction with Eosinophilia and Systemic Symptoms , Kounis syndrome | Jan,2023 |
| Erythromycin | Erythrodar Forte | 4.8 Undesirable effects | Rash | Aug, 2024 |
| Amoxicillin | Amoxil | 4.4 Special Warnings and Special Precautions for Use , 4.5. Interactions with other medicinal products , 4.8 Undesirable effects | Hypersensitivity reactions can also progress to Kounis syndrome, Drug-induced enterocolitis syndrome, acute renal injury. Interactions with probenecid such as methotrexate. Linear Immunoglobulin A (IgA) disease, Aseptic meningitis, Kounis syndrome, Drug-induced enterocolitis syndrome, Crystalluria | Jan,2023 |